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Triple negative breast cancer (TNBC) is characterized by multiple genetic events occurring in concert to drive
pathogenic features of the disease. Here we interrogated the coordinate impact of p53, RB, and MYC in a genetic model
of TNBC, in parallel with the analysis of clinical specimens. Primary mouse mammary epithelial cells (mMEC) with
defined genetic features were used to delineate the combined action of RB and/or p53 in the genesis of TNBC. In this
context, the deletion of either RB or p53 alone and in combination increased the proliferation of mMEC; however, the
cells did not have the capacity to invade in matrigel. Gene expression profiling revealed that loss of each tumor
suppressor has effects related to proliferation, but RB loss in particular leads to alterations in gene expression
associated with the epithelial-to-mesenchymal transition. The overexpression of MYC in combination with p53 loss or
combined RB/p53 loss drove rapid cell growth. While the effects of MYC overexpression had a dominant impact on
gene expression, loss of RB further enhanced the deregulation of a gene expression signature associated with invasion.
Specific RB loss lead to enhanced invasion in boyden chambers assays and gave rise to tumors with minimal epithelial
characteristics relative to RB-proficient models. Therapeutic screening revealed that RB-deficient cells were particularly
resistant to agents targeting PI3K and MEK pathway. Consistent with the aggressive behavior of the preclinical models
of MYC overexpression and RB loss, human TNBC tumors that express high levels of MYC and are devoid of RB have a
particularly poor outcome. Together these results underscore the potency of tumor suppressor pathways in specifying
the biology of breast cancer. Further, they demonstrate that MYC overexpression in concert with RB can promote a
particularly aggressive form of TNBC.
Introduction
Breast cancer is a heterogeneous disease that is categorized by
defined subtypes.1,2 This classification is based on the presence of
the estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor (HER2). Targeted ther-
apies have been developed for receptor-positive breast cancers
that have proven to be effective (e.g. Tamoxifen, Herceptin).3-5
However, the triple negative breast cancer (TNBC) does not
express ER, PR, or HER2; therefore, these cases are historically
treated with systemic chemotherapy.6,7 TNBC is known to be
highly aggressive and associated with poor prognosis. Recent
studies indicate that TNBC itself is likely a collection of discrete
diseases.8 Aggressive forms of TNBC are characterized by the
expression of basal or mesenchymal programs.2,8 In fact, the
basal-like form of TNBC is the dominant subtype and is charac-
terized by deregulated cell cycle control and loss of tumor sup-
pressor. Particularly basal-like breast cancers exhibit frequent
ocerexpression/amplification of MYC and loss of p53 and RB
tumor suppressors.1,8,9 Interestingly, despite these emerging
genetic hallmarks of TNBC and basal-like breast cancer, the dis-
crete mechanistic interactions between tumor suppressors and
oncogenic drivers remains surprisingly obscure.
The relationship between oncogenic drivers, MYC in particu-
lar, and disease phenotypes is exceedingly complex.10-12 MYC is
a well-known oncogene that has a profound impact on gene
expression through a variety of mechanisms. In particular, MYC
broadly regulates transcription in and induces a host of genes
that directly drive proliferation or invasion in specific contexts to
fuel tumor development.13-16 Interestingly, some of these fea-
tures are shared by MYC and RB through regulation of
E2F1.17,18 Although, these shared molecular features are indica-
tive of cooperation, the functional cross-talk between MYC and
RB in cancer is surprisingly murky. In retinoblastoma which
invariably lose RB, there is frequent amplification of N-MYC.19
However, cell and mouse models of cancer driven by MYC can
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show limited effects of RB loss on tumor development or in some
cases apparent antagonism.20,21 Therefore, it seems that the inter-
action between these factors is conditioned by the cell context,
and it is largely unknown how they would functionally interact
in the context of breast cancer.
Outside of the well-established roles of the MYC and RB
pathways in cell growth, both molecules have been associated
with epithelial-to-mesenchymal transition (EMT) and invasion
in various cancer types.15,18,22-24 The role for MYC in EMT and
invasion has been described as context-specific, likely the result
of a combination of deregulated signaling factors and dependent
on additional genetic alterations. Similarly, while inactivation of
RB has been associated with EMT and invasive phenotypes in
cultured cells and mouse models,25-28 the mechanisms associated
with this phenotype remain unclear. Interestingly, mesenchymal
transitions can be associated with therapeutic resistance.
Although it has been proposed that RB-deficiency alters response
to a variety of therapies although this has largely been ascribed to
deregulated cell cycle transitions.29,30
The current study examined the interaction of the MYC and
RB pathways in mammary tumorigenesis. Results indicate that
deregulation of the RB pathway cooperates with MYC overex-
pression to promote enhanced cell invasion and disease progres-
sion. Furthermore, RB-deficiency was associated with differential
response to multiple clinically relevant therapeutics. In human
TNBC samples the combined overexpression of MYC and loss
of RB was associated with poor outcome.
Results
Loss of RB/p53 in mouse mammary epithelial cells promotes
deregulated cell proliferation
To investigate the impact of genetic loss of specific tumor
suppressors on tumorigenesis, mouse mammary epithelial cells
(mMECs) were isolated from mice harboring conditional
alleles of the RB1 and/or the TP53 gene. Cultured mMECs
were infected with Cre-recombinase encoding or control
adenoviruses. The infection resulted in efficient gene recombi-
nation as confirmed by PCR (Fig. 1A). Analysis of cell cycle
distribution was determined by flow-cytometry. As shown in
Fig. 1B, loss of either RB or p53 resulted in enhanced BrdU
incorporation compared to wild-type mMECs. Interestingly,
loss of p53 had a more significant impact on proliferation
than loss of RB, and combined loss of RB/p53 in this setting
did not significantly enhance proliferation over levels observed
with p53 loss alone (Fig. 1B). Immunoblot analysis demon-
strated elevated levels of proteins involved in cell cycle progres-
sion (i.e. Cyclin A) and DNA replication (i.e., MCM7 and
PCNA) with the loss of either tumor suppressor (Fig. 1C). To
examine the impact of RB/p53 loss on the organotypic behav-
ior of the epithelial cells, 3D cell culture was performed26.
Deletion of RB or p53 resulted in significant increase in acinar
size, but overall structure integrity mirrored that of cell with
intact tumor suppressors (Fig. 1D). The effect of combined
tumor suppressor loss was additive, although acinar integrity
remained largely unaffected (Fig. 1D). Together these data
imply a key role of the 2 tumor suppressors in control of criti-
cal proliferative processes, but not necessarily the conversion
to a malignant phenotype associated with invasive breast
cancer.
Combined loss of RB/p53 in mammary epithelial cells alters
gene expression programs controlling cell growth
The Cancer Genome Atlas data (accessed via CBioportal)
indicates that TP53 loss, as determined by mutation or homozy-
gous deletion, occurs in the vast majority of basal like breast can-
cer (Fig. 2A). In contrast, RB loss as determined by mutation,
homozygous deletion, or significantly reduced expression, occurs
in a subset of such cases (Fig. 2A). Therefore, we evaluated the
specific effect of RB loss upon p53 deficient mMEC cultures by
gene expression profiling (Fig. 2B). Consistent with the additive
effects on proliferation, there were a number of genes that exhib-
ited additive behavior with combined RB and p53 loss. As
expected such genes were over-represented for processes associ-
ated with proliferation including DNA replication and mitosis.
Surprisingly, the deletion of RB resulted in attenuation of multi-
ple genes associated with the epithelial characteristics of the pri-
mary cells, which would be generally indicative of an EMT-like
process (Fig. 2B).
Combined loss of RB/p53 enhances the invasive morphology
of MYC-overexpressing mMECs
MYC overexpression is associated with aggressive tumor
phenotypes and disease progression in breast cancer, particu-
larly TNBC. To model RB-proficient and RB-deficient breast
cancer, we built upon the primary mMEC model through the
overexpression of MYC. The cultures were transduced with a
MYC encoding retrovirus and relative expression was deter-
mined by immunoblotting (Fig. 3A). Compared with the
parental non-transformed p53-deficient or RB/p53-deficient
mMECs, overexpression of MYC further enhanced cell prolif-
eration as demonstrated by levels of proteins involved in cell
cycle progression and DNA replication (Cyclin A, PCNA)
(Fig. 3A). Similarly, there levels of BrdU incorporation were
elevated compared to the primary mMEC cultures (Fig. 3B,
compared to Fig. 1B). In this setting, loss of RB did not result
in deregulated proliferation above that observed with MYC-
overexpression (Fig. 3A and B). Alterations in cell behavior
were more prominent in 3Dcultures, in which both MYC over-
expression p53- and RB/p53- mMECs displayed dense, abnor-
mal acinar structures with irregular edges and lacking a hollow
lumen (Fig. 3C, left panel). Interestingly, loss of RB appeared
to enhance the disorganization of the acini, promoting a
“stellate” morphology with spindle-like branching structures
within the matrigel. Additional analyses of acinar morphology
via E-cadherin immunoflourescence revealed an overall
decrease in E-cadherin expression in both RB-proficient and
RB-deficient MYC-overexpressing acini (Fig. 3C, right panels).
However, unlike the RB-proficient acini that demonstrated a
predominantly “chain-like” mode of invasion through the
matrigel, the RB-deficient cultures displayed fibroblast-like,
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mesenchymal invasion of
single-cells associated
with compete loss of E-
cadherin in the majority
of acini. These data sug-
gest that loss of RB in the
context of MYC-trans-
formed mMECs pro-
motes a more invasive
cellular phenotype.
MYC-overexpressing
mMECs display a gene
expression program that
correlates with human
disease
To examine the transcriptional impact of combined RB/
p53 loss in the context of MYC-induced transformation, gene
expression profiling was performed on MYC overexpressing
p53- and RB/p53- mMECs. Initial analyses demonstrated a
surprisingly similar pattern of gene deregulation in both RB-
proficient and RB-deficient cells in comparison to wild-type
mMECs (Fig. 4A). The overall deregulated gene profiles con-
sisted of the upregulation of genes involved in cellular pro-
cesses such as cell cycle, DNA replication and repair, and
RNA processing, as well as the downregulation of genes
involved in processes including cell differentiation and devel-
opment, and cell/biological adhesion. This was the case
regardless of RB-status. Gene set enrichment analysis (GSEA)
was employed to determine the relationship of differential
gene expression in the MYC driven models vs. established
gene sets. Both upregulated and downregulated gene expres-
sion patterns demonstrated significant enrichment when com-
pared to the recently published human MYC-overexpression
signature (Fig. 4B). Thus, the gene expression profiles gener-
ated as a result of MYC-overexpression in the mMECs
Figure 1. RB/p53 loss in
primary mMECs promotes
enhanced proliferation
and acinar size. (A) The
presence of Cre-recombi-
nase was determined by
RT-PCR and recombination
of the Rb and p53 genes
were determined by PCR
analysis of genomic DNA.
(B) Representative flow
cytometry traces display-
ing cell cycle distribution
(top) and BrdU incorpo-
ration (bottom) are shown.
Average percent BrdU
incorporation was quanti-
fied (*p < 0 .05). (C) Total
protein lysates were immu-
noblotted for the indicated
proteins. Lamin B serves as
loading control. (D) Repre-
sentative phase contrast
images of mMEC acini
grown in matrigel (top)
and E-cadherin staining of
acini (bottom). Phase con-
trast images were used to
measure acini diameters
and> 50 acini were scored
for each genotype (*p < 0
.05).
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significantly correlated with the observed gene expression pro-
files associated with MYC-overexpression in human cells and
tissues. The expression of the genes differentially expressed in
the MYC-driven MMEC model was subsequently evaluated in
human breast cancers in luminal, basal, Her2, or normal-like
subtypes. In this context, the gene expression alterations gener-
ated in the MYC-overexpressing mMECs were most elevated
in basal-like breast cancer (Fig. 4C). These data recapitulate
the finding that MYC-driven gene expression is a predominant
feature of basal-like triple negative breast cancer.
Loss of RB promotes deregulation of genes associated with
cell adhesion and motility
To analyze the potential impact of RB-status on the invasive
phenotype observed in RB-deficient, MYC-overexpressing
mMECs, we directly compared the gene expression profiles of
the MYC overexpressing p53- and RB/p53- mMECs. Despite
the similarities observed between the 2 cell lines when compared
to wild-type mMECs, there are multiple genes that are distinctly
affected by RB-status. Interestingly, these genes are predomi-
nantly associated with cellular processes including cell/biological
Figure 2. Loss of RB and p53 in primary mMECs results in additive deregulation of genes involved predominantly in cell cycle control and proliferation.
(A) Analysis of TCGA data reveals common combined loss of RB and p53 in basal like breast cancer. (B) Additive changes in gene expression as a result
of RB and p53 loss in mMECs compared to wild-type mMECs are displayed as a heat map. Top rated gene ontology results for upregulated (top) and
downregulated (bottom) genes are highlighted in the accompanying tables.
112 Volume 14 Issue 1Cell Cycle
Do
wn
loa
de
d b
y [
Th
om
as 
Jef
fer
so
n U
niv
ers
ity
] a
t 0
7:2
4 0
1 M
arc
h 2
01
5 
adhesion and cell motility. Specifically, loss of RB resulted in a
significant downregulation of genes known to be involved in cell
adhesion (e.g., SVEP1, ADAM23, THBS1/2) and axon guidance
(e.g. SEMA5A, SLIT2, EPHB2) that have been associated with
tumor progression in various cancer types, including breast can-
cer (Fig. 5A, upper table). Additionally, RB loss promoted the
upregulation of genes also involved in cell/biological adhesion
(e.g., CD97, F11R, ITGB7, ITGA3, TGFB2), cell migration
(e.g. TGFB1/2, TGFBR1, ITGA3, FGF10, CD34), and epithe-
lial cell development/differentiation (e.g., KRT6B, KRT14,
FGF2, ID1, SIX1) (Fig. 5A). Combined with our initial observa-
tions that RB loss enhances the invasive phenotype of MYC-
overexpressing mMECs in 3D culture, the deregulated gene
expression profile supported a role for RB in promoting
enhanced motility and invasion. RT-PCR analysis was used to
confirm select up- and down-regulated genes associated with
invasive processes (Fig. 5B). To directly test the impact of RB
loss on invasive properties Boyden Chamber assays were per-
formed. Loss of RB resulted in a significant increase in both cel-
lular migration through the membrane (not shown) and cellular
invasion through a matrix-coated membrane (Fig. 5C). Taken
together, these in vitro results indicate that loss of RB promotes
the deregulation of genes involved in cellular adhesion and motil-
ity, and ultimately enhances the migratory and invasive
Figure 3. Combined loss of RB/p53 enhances the invasive phenotype of MYC-overexpressing mMECs. (A) Total protein lysates were immunoblotted for
the indicated proteins. Lamin B serves as loading control. (B) Representative flow cytometry traces displaying cell cycle distribution (top) and BrdU incor-
poration (bottom) are shown. Average percent BrdU incorporation was quantified. (C) Representative phase contrast images of acini grown in matrigel
(left) and E-cadherin staining of acini (right).
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Figure 4.MYC-overexpressing mMECs exhibit significant gene alterations that correlates with basal-like breast cancer. (A) Changes in gene expression of
RB-proficient (left) and RB-deficient (right) MYC-overexpressing mMECs compared to wild-type mMECs are displayed as heat maps. Top rated gene ontol-
ogy results for upregulated and downregulated genes are highlighted in the accompanying tables. (B) Enrichment analyses of upregulated (top) and
downregulated (bottom) genes in MYCCRB/p53- (left) and MYCCRB-p53- (right) mMECs compared to the human MYC-overexpression gene signature
are displayed. (C) Gene expression profiles of MYCCRBCp53- (top) and MYCCRB/p53- (bottom) mMECs correlated with human breast cancer gene
expression signatures.
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Figure 5. Loss of RB promotes deregulation of genes associated with cell adhesion and motility. (A) Changes in gene expression of RB-proficient versus
RB-deficient, MYC-overexpressing mMECs are displayed as a heat map. Top ranked gene ontology results for upregulated and downregulated genes are
highlighted in the accompanying tables. (B) Selected gene expression levels were evaluated by RT-PCR. (C) Cell invasion of RB-proficient and RB-defi-
cient, MYC-overexpressing mMECs. Average number of cells per field was quantified (*p < 0 .05) (D) The indicated proteins were detected by immuno-
blotting. (E) Cell invasion was determined in the absence or presence of the TGFß inhibitor SB431542 (10 mM). Average number of cells per field was
quantified (*p < 0 .05).
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capabilities of MYC-transformed mammary epithelial cells. A
particularly relevant determinant of invasive potential is through
the TGF signaling. We confirmed that RB deletion was associ-
ated with increased expression of TGF-R1 protein, and invasion
of RB-deleted cells was inhibited through the use of the TGF-
receptor inhibitor SB-431542 (Fig. 5D and 5E). Together these
data support a pathway wherein overexpression of MYC and the
concurrent loss of RB facilitates the accumulation of TGF signal-
ing to drive the invasive potential of cancer cells.
Loss of RB disrupts the epithelial phenotype of MYC-
overexpressing mammary tumors
To determine whether the invasive phenotypes observed in
vitro were relevant to tumor biology, we injected MYC-overex-
pressing p53- and RB/p53- mMECs into the mammary fat pads
of 8-week old nude mice. Analysis of tumor growth over time
did not demonstrate a significant difference in average tumor
growth rate between p53- and RB/p53- MYC-driven tumors
(data not shown). However, a dramatic difference was observed
Figure 6. Loss of RB enhances the invasive phenotype of MYC-overexpressing mammary tumors. Representative images of H&E staining (A), Ki67 stain-
ing and phospho-Ser10 histone H3 (B), and E-cadherin staining (C) in RB-proficient and RB-deficient, MYC-overexpressing xenograft tumors are shown.
Normal mammary gland stained with E-cadherin is included for comparison.
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in the overall architecture of the tumors. RB-proficient tumors
maintained a level of glandular architecture within the mammary
tumors, while RB-deficient tumors display a complete loss of this
architecture and differentiation (Fig. 6A). To assess the prolifera-
tion rates of the p53- and RB/p53- tumors, immunohistochemi-
cal staining for Ki67 (proliferation) and phospho-Ser10 Histone
H3 (mitosis) was performed. As shown in Figure 6B and in
accordance with results observed in vitro, levels of proliferation
and mitoses were similar between the tumor types. In contrast, a
significant difference was observed when analyzing E-cadherin
levels within the tumor tissues. While there is a clear presence of
E-cadherin associated with the glandular structures of the RB-
proficient tumors, E-cadherin was undetectable in RB-deficient
tumors (Fig. 6C). Thus, loss of RB does not impact proliferation
over that observed as a result of MYC-overexpression but has an
influence on the architecture and epithelial phenotype of the
tumor tissue.
RB-deficiency has a significant impact on therapeutic
sensitivity
The association of RB-status with invasive properties of MYC-
transformed mMEC led us to determine how such genetic altera-
tions alter the response to therapeutic interventions. For an unbi-
ased assessment of the effect of RB-status on therapeutic
sensitivity a panel of 304 drugs were screened. As shown in
Figure 7A, the majority of drugs exhibited similar activity against
both models irrespective of RB-status. Chemotherapeutic agents
had generally similar efficacy against RB-proficient and deficient
models (Fig. 7B). It has recently been reported that MYC-driven
tumors are specifically sensitive to CDK9 inhibition. Consistent
Figure 7. Loss of RB results in resistance to specific targeted therapies. (A) A library of 304 compounds was screened against the indicated cell lines, with
cell viability measured by cell-titer-glow. (B and C) Data showing the relative viability of the indicate cell populations following challenge with specific
therapeutic agents.
www.tandfonline.com 117Cell Cycle
Do
wn
loa
de
d b
y [
Th
om
as 
Jef
fer
so
n U
niv
ers
ity
] a
t 0
7:2
4 0
1 M
arc
h 2
01
5 
with that finding we found that the MMEC over expressing
MYC were particularly sensitive to dinaciclib and flavopiridol,
and this response was not modified by RB-status. In contrast,
many targeted agents that impact on MEK and PI3K/mTOR sig-
naling pathways had less efficacy in RB-deficient cells (Fig. 7C).
These findings suggest that outside of conventional chemother-
apy, MYC-driven RB-deficient tumors may represent a particular
challenge for treatment.
Combined MYC and RB loss is associated with poor prog-
nosis: To determine the relationship of these findings with the
pathology of human breast cancer the expression of MYC and
RB were evaluated by immunohistochemistry in a cohort of
TNBC cases. MYC exhibited diverse nuclear staining across
TNBC cases from exceedingly low nuclear staining, to robust
staining in the majority of cells (Fig. 8A). RB nuclear staining
was observed at relatively homogeneous levels in »60% of tumor
cases, whereas »40% of cases exhibited loss of the staining spe-
cific to the nuclear compartment (Fig. 8A). High MYC expres-
sion was not associated with survival, while trending to poor
outcome (Fig. 8B). RB loss consistent with other studies is associ-
ated with improved outcome in this cohort (in preparation).
However, the subset of cases with combined RB loss and high
expression of MYC were associated with poor prognosis when
compared across all cases in the cohort (Fig. 8C). Consistent
with these combined findings, MYC had a particularly significant
impact on the RB-negative tumors in this cohort (Fig. 8D).
Together these findings indicate that composite MYC-overex-
pression and RB loss are associated with poor outcome in TNBC.
Discussion
TNBC is particularly aggressive and known to be associated
with poor clinical outcome.31,32 Here we modeled loss of 2
tumor suppressors that are believed to “drive” the biology of
TNBC. Mutation of p53 occurs in >80% of TNBC, of which
approximately 40% harbor loss of RB.1 Given the high-fre-
quency of p53 mutations in breast cancer, it is believed that this
represents an obligatory event in disease. Similarly, RB loss is
known to occur during the in situ carcinoma stage of breast can-
cer and is strongly associated with progression to invasive breast
cancer.33,34 Therefore, these events and their coordination are
particularly important for TNBC. RB loss has been shown in
many model systems to promote deregulated cell cycle progres-
sion and cell growth.35,36 This was also observed in the context
of primary mMEC, wherein loss of RB with or without the com-
bined effects of p53-deficiency resulted in increased cell prolifera-
tion and acini size. However, despite loss of RB and p53
functions, the critical adhesion and structural components of the
epithelial cells and acini remained intact. Thus, in spite the
important roles of these 2 tumor suppressors additional events
are clearly required to drive the transformation in this model.
While TNBC is dominated by tumor suppressor loss, deregula-
tion of MYC has emerged as a key oncogenic event. In analysis of
TCGA data, »30% of cases harbor MYC amplification, and
MYC overexpression is often observed in triple negative breast
cancer. Furthermore, the MYC gene expression signature is
enriched in TNBC.11,13,37 In the mMEC models, MYC-overex-
pression potently yielded oncogenic transformation of both p53-
and RB/p53- cells. Correspondingly, such models harbored
highly deregulated MYC transcriptional signature indicative of
basal breast cancer.
This model provided the specific opportunity to define features
specific to RB-positive vs. RB-negative models of disease. Gene
expression profiling in the absence of MYC demonstrated that RB
loss had an expected affect on proliferation-associated genes and
harbored additive features with p53 loss. Additionally, RB loss
Figure 8. MYC overexpression in conjunction with RB loss is associated
with poor prognosis. (A) representative images of MYC and RB immuno-
histochemistry. (B–D) Kaplan-Meier analysis for the association of MYC
and RB status with overall survival (OS).
118 Volume 14 Issue 1Cell Cycle
Do
wn
loa
de
d b
y [
Th
om
as 
Jef
fer
so
n U
niv
ers
ity
] a
t 0
7:2
4 0
1 M
arc
h 2
01
5 
also contributed to deregulation of genes involved in epithelial
development and immune function, which is consistent with an
emerging literature.27,28,38 It should be noted that we did not
observe evidence of a “full-fledged” EMT as would be evidenced
by enhanced expression of vimentin in the tumor cells. These data
agree with other studies defining the loss of epithelial features as a
consequence of RB deletion26; however, as described above, in the
absence of an oncogenic driver such changes in gene expression
translated to relatively modest effects on cellular behavior. In the
context of MYC overproduction, RB loss was not associated with
additional deregulation of cell cycle control. This was perhaps not
surprising since MYC is known to influence the expression of a
vast array of genes that encompasses those genes regulated by the
RB pathway. Interestingly, RB loss was observed to specifically
impact a subset of genes predominantly involved in cell adhesion
and motility. This finding was accompanied by functional studies
indicating a more invasive phenotype. Importantly, xenograft
tumors demonstrated a highly de-differentiated phenotype and
loss of epithelial characteristics. This finding is consistent with
emerging literature that RB loss is associated with EMT-like tran-
sitions characterized by loss of epithelial character of the
tumors.22,27 Analyses of the mechanisms associated with these
invasive properties revealed RB-dependent deregulation of TGF
signaling pathways. Overexpression of TGF related genes was
observed at the RNA level, and confirmed at the protein level for
TGFR1. Pharmacological inhibition of TGF signaling confirmed
a significant effect on the invasive potential of RB-negative mod-
els. Taken together, these data suggest that loss of RB in the con-
text of MYC-transformation promotes deregulation of the TGF
pathway to enhance cell invasion and disease progression. Consis-
tent with the observation that RB loss yields a particularly aggres-
sive phenotype in concert with MYC overexpression, triple
negative breast cancers that exhibited compound RB loss and
MYC overexpression had a particularly poor prognosis.
One of the key challenges of treatment of TNBC is the pau-
city of targeted therapies. In part, this is because the key genetic
events in TNBC and basal-like breast cancer such as MYC, p53,
and RB are not currently actionable. Here we explored the possi-
bility that the genetic difference between and p53 and p53/RB-
deficient tumors could yield tumor specific vulnerabilities. RB
loss has been shown to yield sensitivity to chemotherapy in a
number of preclinical models, including recent drug screening
studies.39,40 Surprisingly, in a screen of 304 targeted cancer
drugs, there were very few agents that harbored reproducible
enhanced sensitivity against RB-deficient cells, including chemo-
therapy. In fact, RB loss generally elicited bypass of the targeted
agents employed, with general resistance toward PI3K, mTOR
and MEK inhibitors. In clinical cases of TNBC, RB loss has
been paradoxically associated with improved clinical outcome,
likely due to an association with improved response to chemo-
therapy.41-43 We have also observed this finding in the TNBC
cohort analyzed here. However, MYC overexpression in concert
with RB loss served to define a subset of patients with particularly
poor prognosis. This finding suggests that during the etiology of
MYC/RB deficient cancers, the intrinsic sensitivity to chemother-
apy imparted by RB loss is mitigated. Therefore, such tumors
would be both particularly aggressive and challenging to treat.
Together, these data underscore the challenge of treating TNBC,
wherein the tumor genetics could have a particularly pronounced
impact on treatment outcomes.
Materials and Methods
Mouse mammary epithelial cell (mMEC) isolation and sub-
culturing
Primary mouse mammary epithelial cells (mMECs) were iso-
lated from 8-week old female mice harboring floxed Rb (RbloxP/
loxP) and/or p53 (p53loxP/loxP) genes.44 mMECs were sub-cul-
tured in DMEM/F12 supplemented with 5% horse serum,
20 ng/mL EGF, 10 mg/ml insulin, 1 ng/ml cholera toxin,
100 mg/ml hydrocortisone, 100 U/ml penicillin/streptomycin
and 2 mM L-glutamine at 37!C in 5% CO2.
RB/p53 deletion and MYC overexpression
Three days post-isolation, mMECs were infected with adeno-
viral constructs expressing green fluorescent protein (GFP) or
GFP and Cre recombinase (GFP-Cre), with an infection effi-
ciency of 90–95% as determined by GFP immunofluorescence.
Recombination at the Rb and/or p53 loci was confirmed by
genomic DNA isolation and polymerase chain reaction (PCR) as
previously described.44 MYC overexpression was achieved via ret-
roviral transduction using an MSCVpuro-MYC expression con-
struct generously provided by Dr. Scott Lowe.
Immunoblotting/RT-PCR
Total cell lysates were resolved using SDS-PAGE and trans-
ferred to Immobilon-P membranes (Millipore, Bedford, MA).
Proteins were detected using with the following primary antibod-
ies: Santa Cruz Biotechnology – Cyclin A (C-19); Lamin B (M-
20); MCM7 (141.2); PCNA (PC10); MYC (9E10), TGFßR1
(R-20). RNA was harvested from cells using TRIzol (Invitrogen,
Carlsbad, CA) according to manufacturer’s instructions. Super-
script reverse transcriptase (Invitrogen) was used to generate
cDNA with random hexamer primers. qPCR was conducted
using Power SYBR Green (Applied Biosystems). Primer sequen-
ces are available upon request to ESK.
BrdU incorporation and bivariate flow cytometry
Cultured cells were labeled with bromodeoxyuridine (BrdU)
(Amersham Pharmicia Biotech) for one hour prior to harvest.
Cells were then washed with PBS and fixed with cold 70% etha-
nol. Dual analysis of BrdU incorporation and total DNA content
was carried out using bivariate flow cytometry as previously
described45. Data analysis was performed using FlowJo 8.8
software.
Three-dimensional (3D) culturing of mMECs
mMECs were trypsinized and resuspended in Assay Media
(DMEM/F12 supplemented with 2% horse serum, 10 mg/ml
insulin 1 ng/ml cholera toxin, 100 mg/ml hydrocortisone,
100 U/ml penicillin/streptomycin and 2 mM L-glutamine) at a
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concentration of 25,000 cells/mL. The cell suspension was mixed
1:1 with Assay Media containing 4% matrigel and 10 ng/mL
EGF. Cells were then seeded at a final concentration of 5,000
cells/chamber in an 8-chambered RS glass slide (Nalgene Nunc.
Naperville, IL) containing 40 mL of matrigel (BD Bioscience)
that was solidified 30 min prior to seeding. Assay Media was
replaced every 3 d during culturing. Acinar size was assessed at
day 8 of culturing by phase contrast imaging with a 20X objec-
tive. Diameters were measured at the middle optical section of
each acinus with the support of Image J software. At least 50
individual acinar structures were scored for each cell popula-
tion.33 Cells were stained for E-Cadherin and Ki67 as previously
described.33
Migration and invasion assays
Cells were seeded at a concentration of 5 £ 104 cells/mL in
serum-free medium into Boyden Chambers (Franklin Lakes, NJ;
BioCoat 354578). The Boyden Chambers were then placed into
wells containing complete growth media as a chemo-attractant,
and cells were incubated for 48 hours (migration assays) or
72 hours (invasion assays). Cells on the outer/lower surface of
the membrane were stained with 2-(4-amidinophenyl)-1H-
indole-6-carboxamidine (DAPI) and visualized on a fluorescent
microscope for quantification. Cells were scored in at least 5
fields per well in triplicate experiments.26
Microarray Analyses
Microarray experiments were performed using the Affymetrix
GeneChip Mouse Gene 1.0 ST arrays (Affymetrix, Santa Clara,
CA). All microarray data are MIAME compliant and have been
deposited in Gene Expression Omnibus (GEO; accession num-
ber GSE40545).
Differential expression analysis
Differential gene expression analysis expression analysis
between sample conditions samples was using a 2-sample t-test
with unequal variance. To account for multiple testing, p-values
were adjusted based on the estimated false discovery rate (FDR).
For increased statistical power, genes with variance below the
50th percentile or expressed below the 25th percentile in over
90% of the samples being compared were assigned an adjusted p-
value of 1 and filtered out prior to FDR estimation. Differentially
expressed genes were identified as those with an adjusted p-value
! 0.05 and minimum 2 absolute fold change.
Drug Screening: A library of 304 drugs agents from Selleck
Chemical were utilized for the drug screening (see supplemental
information). Compounds were diluted in DMSO to 0.5 M
concentration in 96-well plates. Cell were trypsinized and 5,000
cells were plated per well, and left to adhere overnight. Drugs
were administered for a final concentration of 2.5 mM. Follow-
ing 72 hours of treatment, cell viability was assessed using Cell-
Titer-Glo! Luminescent Cell Viability Assay. The relative
fluorescent units were recorded and analyzed by a BIOTEK plate
reader and Gen5 software. Data analysis was performed using
DRUG-DECODE macro (developed by David Haan, UT
Southwestern).
Mammary fatpad injections and analysis of tumor volume
Animal experiments were carried out in accordance with the
NIH Guide for Care and Use of Laboratory Animals and with
approval from the Institutional Animal Care and Use Commit-
tee. Cells were trypsinized and resuspended in media at a con-
centration of 10 £ 106 cells/ml. For mammary fatpad
injections, 8-week old female athymic nude mice were anesthe-
tized via isoflourane, the inguinal gland was exposed via Y-inci-
sion of the abdomen, and 1 £ 106 cells were injected into the
fatpad using a Sub-Q 26G5/8 needle. Mice were euthanized
once tumor volume reached 200–300 mm3. Tumors were
extracted and fixed in 10% neutral buffered formalin (NBF),
paraffin-embedded, and cut into 5 mm sections for histology/
immunohistochemistry.
Immunohistochemistry/immunofluorescence in mouse
tumor tissue sections
Tissue sections were deparaffinized in xylene followed by
rehydration through a gradient of ethanol washes. Sections were
stained with Hematoxylin and Eosin (H&E) using standard pro-
cedures. In addition, expression of Ki67, and phospho-histone
H3 Serine10 (pSer10) were detected and counterstained with
hematoxylin as previously described.46 E-cadherin was detected
by immunofluorescence microscopy and counterstained with
DAPI as previously described.26 Primary antibodies used for
immunohistochemistry and immunofluorescence: Ki67 (Dako);
pSer10, rabbit polyclonal (Upstate Biotechnology); and E-cad-
herin (Dako).
Staining of TNBC patient cohort
The cohort employed for staining has been previous
described.47 The staining approach for RB has been previously
published.33 The tissue microarray was stained with MYC anti-
body (Biocare Medical, Clone Y69 1:50). An established cut-
point (40%) was used for dichotomizing MYC high vs. low
expression levels.48 Images were captured using an Aperio scan-
ner, and statistical survival analysis was performed using Graph-
Pad-Prism.
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